Christine A. Poon - Oct 29, 2025 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/ Christine A. Poon
Stock symbol
REGN
Transactions as of
Oct 29, 2025
Transactions value $
$537,587
Form type
4
Date filed
10/31/2025, 04:09 PM
Previous filing
Sep 12, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
POON CHRISTINE A Director 777 OLD SAW MILL RIVER ROAD, TARRYTOWN /s/ Christine A. Poon 2025-10-31 0001189014

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $3.38M +6.5K +276.36% $520.01 8.85K Oct 29, 2025 Direct
transaction REGN Common Stock Sale -$424K -650 -7.34% $652.68 8.2K Oct 29, 2025 Direct F1
transaction REGN Common Stock Sale -$1.79M -2.74K -33.35% $653.50 5.47K Oct 29, 2025 Direct F2
transaction REGN Common Stock Sale -$1.25M -1.92K -35.03% $654.42 3.55K Oct 29, 2025 Direct F3
transaction REGN Common Stock Sale -$65.5K -100 -2.82% $655.10 3.45K Oct 29, 2025 Direct F4
transaction REGN Common Stock Sale -$467K -712 -20.63% $656.50 2.74K Oct 29, 2025 Direct F5
transaction REGN Common Stock Sale -$255K -388 -14.16% $657.29 2.35K Oct 29, 2025 Direct F6
transaction REGN Common Stock Options Exercise $1.41M +2.71K +115.31% $520.01 5.06K Oct 30, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -6.5K -70.56% $0.00 2.71K Oct 29, 2025 Common Stock 6.5K $520.01 Direct F7
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -2.71K -100% $0.00 0 Oct 30, 2025 Common Stock 2.71K $520.01 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents volume-weighted average price of sales of 650 shares of Company stock on October 29, 2025 at prices ranging from $652.31 to $652.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
F2 Represents volume-weighted average price of sales of 2,735 shares of Company stock on October 29, 2025 at prices ranging from $653.05 to $653.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
F3 Represents volume-weighted average price of sales of 1,915 shares of Company stock on October 29, 2025 at prices ranging from $654.01 to $654.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
F4 Represents volume-weighted average price of sales of 100 shares of Company stock on October 29, 2025 at prices ranging from $655.02 to $655.16. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
F5 Represents volume-weighted average price of sales of 712 shares of Company stock on October 29, 2025 at prices ranging from $656.33 to $656.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
F6 Represents volume-weighted average price of sales of 388 shares of Company stock on October 29, 2025 at prices ranging from $657.02 to $657.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
F7 The stock option vested in three equal annual installments, commencing one year after the date of grant.